Stoke Therapeutics (STOK) Cash from Financing Activities (2018 - 2026)

Stoke Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $84.3 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 6037.34% year-over-year to $84.3 million; the TTM figure through Mar 2026 stood at $180.3 million (up 37.93% YoY), while the FY2025 annual figure was $97.4 million, down 25.71% from the prior year.
• Cash from Financing Activities was $84.3 million for Q1 2026 at Stoke Therapeutics, down from $92.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $120.6 million in Q2 2024 to a low of $43000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $24.2 million across 5 years, with a median of $3.1 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 251254.17% in 2024, then plunged 99.54% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $43000.0 in 2022, then soared by 16976.74% to $7.3 million in 2023, then tumbled by 92.26% to $568000.0 in 2024, then soared by 16157.22% to $92.3 million in 2025, then fell by 8.68% to $84.3 million in 2026.
• The last three Cash from Financing Activities figures came in at $84.3 million (Q1 2026), $92.3 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.